Looked at the interims back in early Feb. Massive negative EBIT and a 13.5 mn forward contract closure producing a positive operating cash flow when it would have been negative.
Put the unrealised gain on biologicals $30.7 mn further down the revenue statement.
Fish deaths are way up apparently which is why even though GAAP allows it you don't put unrealised gains on biologicals above the EBIT line.
The signs were there.
The announcement points out positive pro forma EBITDA. This is really a nonsense measurement IMHO although it's popular (for obvious reasons). Depreciation is real.
Will have the annuals' analysis up a few days after they publish the financial statements.
In the mean time here's Feb's very basic interim analysis:
https://recastinvestor.substack.com/...aland/comments
Bookmarks